Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Phenylbutyrate in Obese and Prediabetics
NCT05028803Completed
- Sponsor
- University of Nottingham
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sodium phenylbutyrate in obesity and prediabetes, sponsored by University of Nottingham. Primary endpoint: Serum branched chain amino acids levels at 3 weeks. Started Sep 2021; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
obesityprediabetes
Beyond the preview
Go deeper on NCT05028803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028803.